droplet digital PCR
The firm shared performance study results at a recent meeting and said it has begun processing samples for its first major pharma customer.Â
Bio-Rad Q3 Revenues Jump 15 Percent
Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.
Biodesix Prices $72M IPO
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Bio-Rad Q2 Revenues Fall 6 Percent on COVID-19 Impact
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
Bio-Rad Laboratories Gets FDA Emergency Use Authorization for ddPCR COVID-19 Assay
The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.
Feb 10, 2020
Aug 1, 2019
Bio-Rad Q2 Revenues Down 1 Percent
May 8, 2019
Bio-Rad Laboratories Reports Flat Q1 Revenues
Feb 28, 2019
Bio-Rad Q4 Revenues Down 1 Percent, Beat Estimates
Feb 22, 2019
Oct 25, 2018
Aug 7, 2018
Bio-Rad Q2 Revenues Jump 14 Percent
May 8, 2018
Bio-Rad Q1 Revenues Rise 10 Percent
Nov 17, 2017
Nov 2, 2017
Bio-Rad Q3 Revenues Grow 5 Percent
Oct 16, 2017